TearLab Corp fka TEAR

[ash111]

commercial system. The market research firm, “Markets and Markets” reports the global market for point-of-care testing will reach $37.0 billion annually by 2021
http://www.marketsandmarkets.com/PressReleases/point-of-care-diagnostic.asp

Fourth Quarter and Year End 2016 Financial Results:

* Achieved full-year 2016 revenue of $28.0 million, an increase of 11% over $25.2 million in 2015

* Reduced loss from operations by 49% compared to 2015, from $31.5 million to $16.0 million

* Received CE Mark approval for next generation platform, providing regulatory clearance in the European Union and European Free Trade Association member countries

* Received regulatory approval from the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) in Mexico
Received regulatory approval in the Republic of Korea by the Ministry of Health and Welfare
Submitted regulatory filing for approval in the Federative Republic of Brazil

* Launched the TearLab Osmolarity System in the Republic of India through partner My HealthSkape PVT Ltd.

a big winner. cap is really a joke.

Cash/share alone >3
5m O/S
mega commerical approval milestone...

C.C on Monday, more eyes.